AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05424679 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safety Planning Intervention
Description: The Safety Planning Intervention is a brief intervention that directly targets suicide risk with demonstrated efficacy and is a recommended best practice for suicide prevention. The intervention aims to provide participants with an individualized set of steps that can be used progressively to both reduce risk and maintain safety when under particular stress. It also includes a series of brief telephone calls to revise the safety plan and facilitate connections to care. The study team will adapt the intervention to target a larger range of mental health distress.
Study NCT05424679 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caring Contacts
Description: Caring contacts is a cost and time effective suicide prevention intervention. It traditionally utilizes letters and postcards that are sent to an individual to remind them that they are cared about and that they matter. Research suggests that this intervention significantly reduces the likelihood of dying by suicide and suicide attempt over a person's lifetime. This intervention has the potential to reach more individuals at risk in the community. In this study, the research team will allow participants to receive these messages by postcard/MMS and will adapt the intervention to align with cultural values.
Study NCT06377618 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Resistance Training and Core Strengthening Exercises Group
Description: The regimen includes resistance training (using bands, weights, and bodyweight for major muscle groups) and core strengthening (targeting abdominal, lower back, hip, and gluteal muscles) exercises.
Study NCT06377618 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Resistance Training and Core Strengthening Exercises Group Plus Vitamin D Supplementation
Description: Group 1 Intervention plus Vitamin D Supplementation: Daily vitamin D supplementation, with the dosage adjusted based on initial serum 25(OH)D levels to achieve and maintain optimal vitamin D
Study NCT04650594 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MUTARS® modular reconstruction prostheses
Description: Patients with MUTARS® modular reconstruction prostheses following primary or secondary knee bone malignancy with minimal follow-up of one year
Study NCT03678467 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: EB-CMF
Description: Autologous, anatomically shaped bone graft
Study NCT05624814 — intervention group
Intervention type: OTHER
Intervention: Standard therapies
Description: Standard therapies for chronic low back pain are pharmacological, psychological, physical and occupational therapies or surgery.
Study NCT05236868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seltorexant
Description: Seltorexant will be administered orally as a tablet and as an intravenous infusion of 14C-seltorexant.
Study NCT05134363 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine Hydrochloride 0.5 mic/kg bolus
Description: comparison between two bolus doses of dexmedetomidine with a placebo group
Study NCT05134363 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine Hydrochloride 0.75 mic/kg bolus
Description: comparison between two bolus doses of dexmedetomidine with a conventional group receiving ondansetron.
Study NCT05134363 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: equal volume of normal saline
Study NCT03615547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomifene Citrate
Description: After randomization, the andrologist will give a prescription with the first three months of treatment (Clomifene Citrate or placebo) to be collected to the local hospital pharmacy. The andrologist will be blind of the treatment arm.~Treatment unit and their shipment to local pharmacy will be provided and organized by the East group pharmacy of the Hospices Civils of Lyon which is the coordination pharmacy for this study. Prescription and delivery will be renewed for three months at the 3 month and 6 months visit.~The experimental treatment consists in a daily dose of 50mg of Clomifene Citrate per os during 9 months followed by a second TESE if no spermatozoid has been obtained from semen. The dose level was set according to Chua et al 2013 (cf 1.2.2). One capsule containing 50 mg of CC will be orally administered in the morning every day.
Study NCT03615547 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo treatment consists in a daily dose of 50mg of lactose monohydrate per os during 9 months followed by a second TESE if no spermatozoid has been obtained from semen. The capsule containing the placebo will have the exact same size, weight, color, taste and will be delivered in the exact same condition as the experimental treatment capsule.
Study NCT04927936 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaccination once with Janssen vaccine (only priming)
Description: Vaccination (priming) with janssen vaccine. There is no boosting.
Study NCT04927936 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination with Janssen vaccine followed with Janssen vaccine (homologous boosting).
Description: Vaccination (priming) with janssen vaccine. There is boosting with Janssen vaccine.
Study NCT04927936 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination with Janssen vaccine followed with Moderna vaccine (heterologous boosting).
Description: Vaccination (priming) with janssen vaccine. There is boosting with Moderna vaccine.
Study NCT05701436 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 130 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
Study NCT05701436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
Study NCT05701436 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 20 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
Study NCT05701436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 20 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
Study NCT05701436 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lobaplatin
Description: 50 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
Study NCT05701436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lobaplatin
Description: 50 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
Study NCT05701436 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 50 mg per square body surface area was used for monthly transhepatic arterial infusions.
Study NCT05701436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 50 mg per square body surface area was used for monthly transhepatic arterial infusions.
Study NCT05701436 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin, Leucovorin, fluorouracil
Description: Oxaliplatin(130 mg per square body surface area), Leucovorin(400 mg per square body surface area), and fluorouracil(2800 mg per square body surface area) were used for monthly transhepatic arterial infusions.
Study NCT05701436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin, Leucovorin, fluorouracil
Description: Oxaliplatin(130 mg per square body surface area), Leucovorin(400 mg per square body surface area), and fluorouracil(2800 mg per square body surface area) were used for monthly transhepatic arterial infusions.
Study NCT05701436 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lobaplatin, Raltitrexed
Description: Lobaplatin(50 mg per square body surface area) and Raltitrexed(3 mg per square body surface area) were used for monthly transhepatic arterial infusions.
Study NCT05701436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lobaplatin, Raltitrexed
Description: Lobaplatin(50 mg per square body surface area) and Raltitrexed(3 mg per square body surface area) were used for monthly transhepatic arterial infusions.
Study NCT05597332 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Care bundle for AKI
Description: To maintain mean arterial pressure (MAP) ≥ 65 mmHg; to keep the patient euvolemic; to avoid nephrotoxic drugs; to adjust dose of medication for kidney function; to exclude urinary obstruction; to monitor urine output and serum creatinine levels.
Study NCT05215730 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MedCu wound dressings with copper oxide (COD)
Description: Patients whose foot wound is indicated for VAC treatment will be randomized to either treatment arm after signing informed consent.
Study NCT05400421 — intervention group
Intervention type: DEVICE
Intervention: System & Method for Monitoring Aortic Pulse Wave Velocity & Blood Pressure
Description: Carotid-femoral aortic pulse wave velocity will be compared against values collected from the oximeter system. The former is assessed by placing piezoelectric pressure sensors at three locations: the right common carotid artery, the right common femoral artery (groin), and the right superficial femoral artery (thigh). The oximeter will be secured on the right index finger. Simultaneous data collection will occur for both methods, with each trail lasting 60 seconds.
Study NCT04927936 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination with Janssen vaccine followed with Pfizer vaccine (heterologous boosting).
Description: Vaccination (priming) with janssen vaccine. There is boosting with Pfizer vaccine.
Study NCT06346925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herombopag Olamine Tablets
Description: Three Herombopag Olamine Tablets is administered to healthy subjects.
Study NCT05187520 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Patient-controlled epidural analgesia (PCEA)
Description: Epidural analgesia is a technique of neuraxial block by placement of a 20G polyether epidural catheter into the epidural lumen and fixed at the desired depth, and analgesic effect is usually achieved by administration of mixture of local anesthetics and opioids using a programmed pump.
Study NCT05187520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naldebain®
Description: Naldebain dissolved in benzyl benzoate and sesame oil (a total volume of 2ml) will be prepared in a 5-ml syringe 30 min before administration. Intramuscular injection into the gluteal muscles will be performed by an anesthesiologist under sonography-guidance.
Study NCT06495463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil
Description: Trifluridine/tipiracil 35 mg/m2 PO twice daily on days 1-5 and day 6-14 off~(choose one combination) : oxalipatin 85mg/m2 IV on day 1 every 14 days or irinotecan 100mg/m2 IV on day 1 every 14 days.
Study NCT05396755 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic retrograde cholangiography (ERC)
Description: invasive evaluation of the biliary tract with ERC and endoscopic interventions every 8 weeks until 6 months (24 weeks)
Study NCT04650919 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total laryngectomy and reconstruction by stented aortic allograft (using human tissue and device).
Description: The procedure consists of 2 operating times:~* Surgery S1 (1st surgical procedure): total laryngectomy and placement of the stented aortic graft (human tissue + device: NOVATECH GSS TM (trademark) TD), under tracheotomy cover.~* Surgery S2 (2nd surgical procedure) (between S1 +24 weeks and S1 +36 weeks) : opening of the proximal part of the graft by endoscopic way with maintenance of the tracheotomy orifice to ensure patient safety.
Study NCT06088511 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Exercise Training
Description: For the 8-week self-management phase, the participants will be recommended to follow the lifestyle interventions to relieve their problems related to sarcopenia. The participants in the experimental group will also be suggested to continually practise exercise training at home for 30 minutes at least 5 times per week. Participants can review the self-learning exercise videos embedded in the System. The exercise trainings include: a) progressive resistance training to improve muscle strength; and b) brisk walking exercise to maintain walkability.
Study NCT06361212 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ethoximod
Description: Ethoximod is a S1P1 modulator.
Study NCT06578871 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity Modulated Radiotherapy (IMRT) to Mucosa at Risk
Description: Patients in Arm 1, after the surgical procedure, will receive radiotherapy to the at-risk mucosa.
Study NCT06578871 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Intervention
Description: These patients will undergo Neck dissection, TORS tonsillectomy (unilateral vs bilateral tonsillectomy at the discretion of the treating physician) + ipsilateral tongue base mucosectomy.
Study NCT06578871 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Intervention
Description: These patients will undergo Neck dissection, TORS tonsillectomy (unilateral vs bilateral tonsillectomy at the discretion of the treating physician) + ipsilateral tongue base mucosectomy.
Study NCT06578871 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiotherapy (IMRT) to Ipsilateral Neck
Description: For Arm1, after the surgical procedure, the patients will receive radiotherapy to the ipsilateral neck. For Arm2, the patients will only receive IMRT to neck, if multiple ipsilateral nodes or single ipsilateral node >3 cm is observed
Study NCT06578871 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity Modulated Radiotherapy (IMRT) to Ipsilateral Neck
Description: For Arm1, after the surgical procedure, the patients will receive radiotherapy to the ipsilateral neck. For Arm2, the patients will only receive IMRT to neck, if multiple ipsilateral nodes or single ipsilateral node >3 cm is observed
Study NCT06361212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethoximod
Description: Ethoximod is a S1P1 modulator.
Study NCT05344209 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UV1
Description: UV1 vaccine
Study NCT05344209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sagramostim
Description: for stimulation of local dendritic cell population to take up the vaccine and to mature into professional APCs
Study NCT05344209 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Anti-PD-1/PD-L1 treatment
Description: either pembrolizumab, atezolizumab or cemiplimab
Study NCT05344209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1/PD-L1 treatment
Description: either pembrolizumab, atezolizumab or cemiplimab
Study NCT05437328 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bi-4SCAR GD2/CD56 T cells
Description: Infusion of bi-4SCAR GD2/CD56 T cells at 10\^6 cells/kg body weight via IV
Study NCT05527418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Dasatinib monotherapy 70 mg/day, during 16 weeks.
Study NCT05527418 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo during 16 weeks.
Study NCT05585801 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom G6 continuous glucose monitor
Description: Continuous glucose monitor will be used to measure interstitial glucose and aid in guiding the insulin therapy to achieve target blood glucose range of 6-10 mmol/l.~In the control group, blood glucose will be measured according to standards of care and a blinded continuous monitor will be used to compare the time i range between the arms.
Study NCT05585801 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Blood glucose measurements according to standards of care
Description: Blood glucose will be measured using point of care glucose meter and standard biochemistry methods. Blinded CGM will be applied to obtain continuous glucose values for post-hoc comparison.
Study NCT06143033 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DIME Beauty Luminosity Eye Serum
Description: Test product contains: Water/Aqua, Organic Aloe Vera Juice, Lycium Barbarum (Goji Berry) Fruit Extract, Vitis Vinifera (Grape Seed) Extract, Cucumis Sativus (Cucumber) Extract, Glycerin, Niacinamide, Squalane, Camellia Seed Oil, DL-Panthenol (Vitamin B5), Carbomer, Sodium Hyaluronate, Ammonium Acryloyldimethyltaurate/VP Copolymer, Phenoxyethenol, Caprylyl Glycol, Acacia Senegal Gum, Caffeine, Helianthus Annuus (Sunflower) Seed Oil, Malus Domestica (Apple) Fruit Stem Cell Extract, Argania Spinosa (Argan) Sprout Stem Cell Extract, Tetrahexyldecyl Ascorbate (Vitamin C), Acetyl Tetrapeptide, Acetyl Hexapeptide-8, Vitamin E Mixed Tocopherols, Sodium Hydroxide.
Study NCT06228690 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gold Fish exercises
Description: Specific exercise for the flexibility of TMJ that will target the Jaw muscles. Frequency: 3 times/week for 4 weeks Intensity: moderate intensity (pain free) Time: 30-45 minutes Type: Gold Fish exercises for jaw flexibility, pain and maximum mouth opening.
Study NCT06228690 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervico-thoracic postural correction training
Description: Cervico-thoracic postural correction training for upper thoracic and neck muscles.~Frequency: 3 times/week for 4 weeks Intensity: moderate intensity (pain free) Time: 30-45 minutes Type: Muscle energy technique to improve range of motion, pain and maximum mouth opening.
Study NCT06228690 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional PT treatment
Description: Conventional PT including Hot Pack for 10mins, Active-Passive neck Stretching Exercise + jaw Isometric Exercises.~* Frequency: hold followed by 5secs rest. 2-3times for 3 times/week for 4 weeks, Intensity: moderate-high intensity (depending on pain tolerance) Time: 30-45 mins for Active-Passive neck Stretching.~* Frequency: 3secs hold, 6 times repetitions for Isometric Exercises. Type: conventional treatment for pain, ROM, MMO.
Study NCT04752332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally.
Study NCT06404983 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Opioid Free Anaesthesia (OFA)
Description: Patients are allocated to receive non-opioid anaesthesia intraoperatively. Patients will receive a mixture of dexmedetomidine, ketamine and lidocaine for intraoperative analgesia.
Study NCT04752332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Adjuvant ET
Description: Administered according to label instructions.
Study NCT04752332 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Adjuvant ET
Description: Administered according to label instructions.
Study NCT04752332 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Administered orally.
Study NCT06425432 — intervention group
Intervention type: DEVICE
Intervention: OVITZ xwave aberrometer
Description: wavefront aberrometer
Study NCT06404983 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional General Anaesthesia (CGA)
Description: Patients are allocated to receive conventional general anaesthesia intraoperatively with the use of fentanyl and morphine for intraoperative analgesia.
Study NCT05152888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Evolocumab is a human monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9). Evolocumab was FDA approved in 2015 for the treatment of hyperlipidemia and subsequently approved in 2017 for the prevention of stroke and heart attack. 140mg single use SureClick autoinjector that is administered subcutaneously once every 2 weeks.
Study NCT03961412 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: family-based intervention
Description: The participants will identify their accompanying influential person(s) (e.g., spouse, partners, parents, children, friends) with whom they will be attending the 1.5-2 hour face-to-face education session on cervical cancer and screening. At the end of the intervention, time will be allowed for questions, as well as distributing fridge magnets and a pamphlet. Fridge magnets contain Pap test guidelines and availability of local clinics. The pamphlet covers the following topics: (a) information about female anatomy and cervical cancer, (b) risk factors for cervical cancer, (c) facts of cervical cancer incidence and mortality, and screening rates among American women, (d) methods to reduce cervical cancer (e.g., HPV vaccination), (e) Pap test procedure, (f) Pap test guidelines, and (g) availability of clinics and cost of Pap test. The participants will be encouraged to spread the message to family members and friends.
Study NCT03961412 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Participant only intervention
Description: Only participant will attend the 1.5-2 hour face-to-face education session on cervical cancer and screening. At the end of the intervention, time will be allowed for questions, as well as distributing fridge magnets and a pamphlet. Fridge magnets contain Pap test guidelines and availability of local clinics. The pamphlet covers the following topics: (a) information about female anatomy and cervical cancer, (b) risk factors for cervical cancer, (c) facts of cervical cancer incidence and mortality, and screening rates among American women, (d) methods to reduce cervical cancer (e.g., HPV vaccination), (e) Pap test procedure, (f) Pap test guidelines, and (g) availability of clinics and cost of Pap test. The participants will be encouraged to spread the message to family members and friends.